IGC Pharma Files Patents for AI Data Harmonization Architecture Covering 15 Alzheimer’s Datasets
IGC Pharma filed utility patent applications covering the architectural framework of its Agentic Harmonization Assistant, an AI-based system that has already harmonized 15 heterogeneous Alzheimer’s disease datasets. AHA advanced to the semi-final stage of a competitive AI evaluation program and will have its development roadmap presented at the ADPD conference.
1. Patent Application Details
IGC Pharma filed utility patent applications to protect the architectural design and harmonization methodologies of its internally developed Agentic Harmonization Assistant (AHA), securing key AI-driven data alignment processes for Alzheimer’s research.
2. AHA Development Progress
The multi-stage AHA system has standardized 15 heterogeneous Alzheimer’s disease datasets—addressing schema definitions, variable encodings and data structures—and advanced to the semi-final round of a competitive AI research evaluation.
3. Upcoming Roadmap Presentation
The company will present additional technical details and a development roadmap for AHA at the upcoming ADPD conference, outlining future integration milestones and planned feature rollouts.
4. Strategic Implications and Next Steps
By strengthening its AI data harmonization IP, IGC Pharma aims to support potential collaborations, integration or licensing opportunities while maintaining focus on its Phase 2 CALMA trial for IGC-AD1.